Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Kidlington. Good find. Exciting times ahead I feel. Onwards & upwards
Here we come
Https://xtalks.com/webinars/are-you-ready-for-eu-ctr-the-challenges-lessons-learned-and-innovations-surrounding-the-new-regulation/
did a industry talk in summer 2022 regarding Clinical trial regulation within the EU. The largest change in clinical trial landscape in 20 years. Obviously PYC dont do clinical trials themselves, but they work out dosing regimen for those in clinical trials.
Seems like he has all the right tools especially regulatory acumen to help PYC navigate the choppy waters of regulatory controls for their Dosing software. Not only in EU, but also in the US.
One thing we do know kid is this is going to be the hot stock this week! I hope it is fruitful for all!
Goldy..... i love your optimism, but they have not! They partook in a paltry £5 in the raise and thats it. Jim holds approx 1.5m and the out going COO has about 600k.
TBH they have "not a lot of skin in the game"
Nothing about PYC is standard practice!
I have long harped on about TR1's not appearing. ZA did appear, and if you got back thru the RNS's he announced his arrival straight after the DosemeRx tie up. He also added, and that corresponded with more TR1 RNS's,. However, he started to sell, and yet no RNS were published to say he was selling and how many he had sold and what was his new holding.
So it was asked at one of the investormeet Q&A's about this, and Jim said it was up to the shareholders themselves to get in touch with the company and tell them about their buys or sells if over 3%! This seems contradictory to other companies, who seem to do the opposite? Jim said that there is "not a insignificant cost" for doing this check, hence why its only every 6 months.
We know GM has been on the register (Aug 14th), but we have no idea when he bought them ( would have been after 14th of Feb thou ) & he may not be there now?
We also had a at least 15 x 250k buys in a few weeks when the SP was 7p a few years ago, never did find out who got them! No TR1 was issued, and yes, it might not have been all the same person.
Incredible day more to come directors been loading up for quite sometime now !!!!
Thanks for the info on the share registrar Kid. Is tht standard practice? Seems peculiar to carry tht out on a semi annual basis and not as and when? Apologies if I am being naive here. It would be great to see a TR-1 for GM via RNS, he may even be adding? Certainly some larger trades appearing today.
Those are all genuine questions Kid, perhaps he has ties to another board elsewhere? It is also valid to ask how he will be paid, particularly knowing current directors take a small package.
I guess we may be able to pick some of these from the next set of accounts.
Genuine questions
How much will he be paid?
Will he get share options?
Does it matter that he has not been a COO before? Could he lack the skills of a more seasoned COO?
In the RNS is says " Dr Sargent will join as a key member of the Company's senior leadership team (but not as a board director) and will report directly to Dr Jim Millen." Why would PYC or new COO not want to be a board director?
It took 5 attempts over 2 days to breech and hold above 2p, was fascinating watching the trade go thru today. Got to 2p and sells came in, got to 1.8p and the buyers returned, some chunky trades to 700k and several 400 / 300k's
Great day all, just read most of the 225 posts today, a month ago, we were averaging about 5!
Gordon, you asked about TR1's
We know there is a Gary Marshall. That info only came to light after Jim does a 6 month refresh of the share register. "if" he is building, then i guarantee we will not find out for another 6 months, anyone who goes TR1 here probably wishes to fly under the radar. I would love a TR1 to appear, from Gary or anyone else, but in the last 5 years, there has only been 1 who appeared, and that was Zahid Ali.
Saying that, there were 2 others before the raise, and they are not shown now, i assume that they are still holding, but their % is less than 3% due to dilution.
Good chance it’ll go there tomorrow seeing that resistance at 2.20 ask got smashed today
Couldn’t buy a bean on the close, they were actually wanting your shares at 2.30, the offer price!! Be surprised if opens on 2.30 tomorrow and if it does there certainly won’t be any stock. Exciting week ahead
Welcome Nael
Previous pessimism regarding future deal flow for Physiomics floored the bid price which gapped down a few weeks back and I got stopped out from a 1% Co. holding. I've been on the sidelines watching the positive divergence in net accumulation within the narrow price range prior to the recent break out.
There are not a large volume of chunky trades coming through yet but it would appear that private investor awareness is steadily improving.
The technology has significant potential IMO. I'll see if my modest limit order works out tommorow.
Hi Jadam
Even 3.5p is only valuing PYC at £4mln which is woefully undervaluing its client base,contract momentum and mgmt
About to crossing the very bullish 200 moving average too so put me down for a 3.5p close tomorrow
This was from Kidlington about 4 weeks ago, do it seems that several people (including Gary and also previous 3% holder Z Ali who we assume isn't there anymore because the new shares have meant he's now slightly under 3% now )have seen something in PYC that's worth being connected with
The article can also be viewed here https://jpet.aspetjournals.org/content/early/2023/06/22/jpet.122.001572
On this link you can see where all the other contributors are academically based/work for. Shows that employees/consultants of PYC are in contact scientifically ( at least) with some big companies ( AZ & GSK) on papers.
David Hodson, Hitesh, Leo and Kayode are Uni Manchester.
James Yates is GSK.
Paul Farrington, Anna Staniszewska, Sofia Guzzetti, Michael Davies are all AstraZeneca
But then again, it could be a good indication that PYC is about to do the same 600% lol, petroinvestor only appears on shares that multibag to deramp them, see what he did on the POS board, look at the sp now
Tend to agree, it’s strange tht an individual not involved in a company holds more than those at the helm. That leads me to believe he sees something of huge interest. If it is the GM of the pharma world who believe it to be then my bet is he is picking up more here on the open market.
Time will tell but history often repeats itself
4 29pm
....that this could be huge!!! I've been following Pyc for a few years thinking they could become big but I have a gut feeling this is going to keep going. Ridiculously low market cap for a company earning money and continually signing new contracts. They are aligned with big names. And Laura keeps on about artificial intelligence dude of things and something is telling me she may b right. This Marshall guy must be impressed or in the know so I think this time Pyc are on an incredible journey . For us loyal shareholders too. Hope it works out for us all
We have lots of links to USA
1) many clients there including Merck
2) new COO
3) personalised dosing tool already been trailed via DoseMeRX and also with other clinicians 3 mths ago
4) we present at the AACR annually (see April RNS) where 100s of the biggest companies are represented (new ,existing and prospective clients)
Someone taking all they could get at close?!?
Very interesting take on the situation Laura, I think if Gary is building we could really be in for a big boost. Perhaps an RNS from the bod confirming his motives or involvement.
On the US point we could also be opening doors with Our new Coo
PYC have their dosing tool, which has been used within Doseme for a few years now ( thou there is some conjecture on this ) It has long been mooted that they want to expand it & be more commercial, especially within the USA pharma field. To do this, their "tool" will need Regulatory approval, especially with the FDA, and PSC help with that. Also FDA have a new thing called "project optimus" & PYC are one of the 1st UK coys attempting to trail blaze this initiative.
PSC say they can help with software and many other things that can get a product off the ground.
There could also be the thorny issue that if this is the Gary Marshall that works for PSC, and has got wind of what PYC are planning to do, and could even be the project leader ( his role )
See the posts from Kidlington re; Gary